These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17194903)

  • 1. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
    Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
    J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
    Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
    Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
    Metharom E; Galettis P; Manners S; Jelinek M; Liauw W; de Souza PL; Hoskins JM; Links M
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):65-74. PubMed ID: 21332653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
    Sugiyama E; Lee SJ; Lee SS; Kim WY; Kim SR; Tohkin M; Hasegawa R; Okuda H; Kawamoto M; Kamatani N; Sawada J; Kaniwa N; Saito Y; Shin JG
    Drug Metab Pharmacokinet; 2009; 24(6):553-6. PubMed ID: 20045991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
    Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
    Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
    Ding X; Chen W; Fan H; Zhu B
    Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
    Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
    Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
    Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
    Xu J; Zhou Y; Zhang J; Chen Y; Zhuang R; Liu T; Cai W
    Clin Chim Acta; 2012 Aug; 413(15-16):1284-7. PubMed ID: 22546611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
    Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
    PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
    Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
    Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
    Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
    Gilbert JA; Salavaggione OE; Ji Y; Pelleymounter LL; Eckloff BW; Wieben ED; Ames MM; Weinshilboum RM
    Clin Cancer Res; 2006 Mar; 12(6):1794-803. PubMed ID: 16551864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
    Saito Y
    Yakugaku Zasshi; 2011 Feb; 131(2):239-46. PubMed ID: 21297369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
    Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
    Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
    Gusella M; Pasini F; Bolzonella C; Meneghetti S; Barile C; Bononi A; Toso S; Menon D; Crepaldi G; Modena Y; Stievano L; Padrini R
    Br J Clin Pharmacol; 2011 Mar; 71(3):437-44. PubMed ID: 21284703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
    Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
    Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.